International Journal of Cancer Management

Published by: Kowsar

Immunotherapy in Multiple Myeloma Using Cancer-Testis Antigens

Soudeh Ghafouri-Fard 1 , * , Mahnaz Seifi-Alan 1 , Roshanak Shamsi 1 and Ali Esfandiary 1
Authors Information
1 Department of Medical Genetics, Shahid Beheshti University of Medical Sciences, Tehran, IR Iran
Article information
  • Iranian Journal of Cancer Prevention: October 28, 2015, 8 (5); e3755
  • Published Online: October 27, 2015
  • Article Type: Review Article
  • Received: August 4, 2015
  • Revised: August 29, 2015
  • Accepted: September 22, 2015
  • DOI: 10.17795/ijcp-3755

To Cite: Ghafouri-Fard S, Seifi-Alan M, Shamsi R, Esfandiary A. Immunotherapy in Multiple Myeloma Using Cancer-Testis Antigens, Int J Cancer Manag. 2015 ; 8(5):e3755. doi: 10.17795/ijcp-3755.

Abstract
Copyright © 2015, Iranian Journal of Cancer Prevention.This is an open-access article distributed under the terms of the Creative Commons Attribution-NonCommercial 4.0 International License (http://creativecommons.org/licenses/by-nc/4.0/) which permits copy and redistribute the material just in noncommercial usages, provided the original work is properly cited.
1. Context
2. Evidence Acquisition
3. Results
4. Conclusions
Acknowledgements
Footnotes
References
  • 1. Dimopoulos MA, Terpos E. Multiple myeloma. Ann Oncol. 2010; 21 Suppl 7-50[DOI][PubMed]
  • 2. Dimopoulos MA, Kastritis E, Anagnostopoulos A. Hematological malignancies: myeloma. Ann Oncol. 2006; 17 Suppl 10-43[DOI][PubMed]
  • 3. Boyle EM, Davies FE, Leleu X, Morgan GJ. Understanding the multiple biological aspects leading to myeloma. Haematologica. 2014; 99(4): 605-12[DOI][PubMed]
  • 4. Huff CA, Matsui W. Multiple myeloma cancer stem cells. J Clin Oncol. 2008; 26(17): 2895-900[DOI][PubMed]
  • 5. Kumar SK, Rajkumar SV, Dispenzieri A, Lacy MQ, Hayman SR, Buadi FK, et al. Improved survival in multiple myeloma and the impact of novel therapies. Blood. 2008; 111(5): 2516-20[DOI][PubMed]
  • 6. Brennan SK, Matsui W. Cancer stem cells: controversies in multiple myeloma. J Mol Med (Berl). 2009; 87(11): 1079-85[DOI][PubMed]
  • 7. Tabarestani S, Ghafouri-Fard S. Cancer stem cells and response to therapy. Asian Pac J Cancer Prev. 2012; 13(12): 5951-8[PubMed]
  • 8. Matsui W, Wang Q, Barber JP, Brennan S, Smith BD, Borrello I, et al. Clonogenic multiple myeloma progenitors, stem cell properties, and drug resistance. Cancer Res. 2008; 68(1): 190-7[DOI][PubMed]
  • 9. Ghafouri-Fard S. Expression of cancer-testis antigens in stem cells: is it a potential drawback or an advantage in cancer immunotherapy. Asian Pac J Cancer Prev. 2015; 16(7): 3079-81[PubMed]
  • 10. Costello RT, Rey J, Fauriat C, Gastaut JA, Olive D. New approaches in the immunotherapy of haematological malignancies. Eur J Haematol. 2003; 70(5): 333-45[PubMed]
  • 11. Klippel ZK, Chou J, Towlerton AM, Voong LN, Robbins P, Bensinger WI, et al. Immune escape from NY-ESO-1-specific T-cell therapy via loss of heterozygosity in the MHC. Gene Ther. 2014; 21(3): 337-42[DOI][PubMed]
  • 12. Rutella S, Locatelli F. Targeting multiple-myeloma-induced immune dysfunction to improve immunotherapy outcomes. Clin Dev Immunol. 2012; [DOI][PubMed]
  • 13. Gorgun GT, Whitehill G, Anderson JL, Hideshima T, Maguire C, Laubach J, et al. Tumor-promoting immune-suppressive myeloid-derived suppressor cells in the multiple myeloma microenvironment in humans. Blood. 2013; 121(15): 2975-87[DOI][PubMed]
  • 14. Atanackovic D, Luetkens T, Hildebrandt Y, Arfsten J, Bartels K, Horn C, et al. Longitudinal analysis and prognostic effect of cancer-testis antigen expression in multiple myeloma. Clin Cancer Res. 2009; 15(4): 1343-52[DOI][PubMed]
  • 15. Locke FL, Nishihori T, Alsina M, Kharfan-Dabaja MA. Immunotherapy strategies for multiple myeloma: the present and the future. Immunotherapy. 2013; 5(9): 1005-20[DOI][PubMed]
  • 16. van Duin M, Broyl A, de Knegt Y, Goldschmidt H, Richardson PG, Hop WC, et al. Cancer testis antigens in newly diagnosed and relapse multiple myeloma: prognostic markers and potential targets for immunotherapy. Haematologica. 2011; 96(11): 1662-9[DOI][PubMed]
  • 17. de Carvalho F, Vettore AL, Colleoni GW. Cancer/Testis Antigen MAGE-C1/CT7: new target for multiple myeloma therapy. Clin Dev Immunol. 2012; 2012: 257695[DOI][PubMed]
  • 18. Bae J, Munshi NC, Anderson KC. Immunotherapy strategies in multiple myeloma. Hematol Oncol Clin North Am. 2014; 28(5): 927-43[DOI][PubMed]
  • 19. Dianatpour M, Mehdipour P, Nayernia K, Mobasheri MB, Ghafouri-Fard S, Savad S, et al. Expression of Testis Specific Genes TSGA10, TEX101 and ODF3 in Breast Cancer. Iran Red Crescent Med J. 2012; 14(11): 722-6[DOI][PubMed]
  • 20. Ghafouri-Fard S, Abbasi A, Moslehi H, Faramarzi N, Taba Taba Vakili S, Mobasheri MB, et al. Elevated expression levels of testis-specific genes TEX101 and SPATA19 in basal cell carcinoma and their correlation with clinical and pathological features. Br J Dermatol. 2010; 162(4): 772-9[DOI][PubMed]
  • 21. Ghafouri-Fard S, Modarressi MH. Cancer-testis antigens: potential targets for cancer immunotherapy. Arch Iran Med. 2009; 12(4): 395-404[PubMed]
  • 22. Ghafouri-Fard S, Modarressi MH. Expression of cancer-testis genes in brain tumors: implications for cancer immunotherapy. Immunotherapy. 2012; 4(1): 59-75[DOI][PubMed]
  • 23. Seifi-Alan M, Shamsi R, Ghafouri-Fard S, Mirfakhraie R, Zare-Abdollahi D, Movafagh A, et al. Expression analysis of two cancer-testis genes, FBXO39 and TDRD4, in breast cancer tissues and cell lines. Asian Pac J Cancer Prev. 2014; 14(11): 6625-9[PubMed]
  • 24. Ghafouri-Fard S, Modarressi MH, Yazarloo F. Expression of testis-specific genes, TEX101 and ODF4, in chronic myeloid leukemia and evaluation of TEX101 immunogenicity. Ann Saudi Med. 2012; 32(3): 256-61[DOI][PubMed]
  • 25. Ghafouri-Fard S, Nekoohesh L, Motevaseli E. Bladder cancer biomarkers: review and update. Asian Pac J Cancer Prev. 2014; 15(6): 2395-403[PubMed]
  • 26. Ghafouri-Fard S, Ghafouri-Fard S. siRNA and cancer immunotherapy. Immunotherapy. 2012; 4(9): 907-17[DOI][PubMed]
  • 27. Ghafouri-Fard S, Shamsi R, Seifi-Alan M, Javaheri M, Tabarestani S. Cancer-testis genes as candidates for immunotherapy in breast cancer. Immunotherapy. 2014; 6(2): 165-79[DOI][PubMed]
  • 28. Ghafouri-Fard S, Rezazadeh F, Zare-Abdollahi D, Omrani MD, Movafagh A. Are so-called cancer-testis genes expressed only in testis? Asian Pac J Cancer Prev. 2014; 15(18): 7703-5[PubMed]
  • 29. Hofmann O, Caballero OL, Stevenson BJ, Chen YT, Cohen T, Chua R, et al. Genome-wide analysis of cancer/testis gene expression. Proc Natl Acad Sci U S A. 2008; 105(51): 20422-7[DOI][PubMed]
  • 30. Atanackovic D, Arfsten J, Cao Y, Gnjatic S, Schnieders F, Bartels K, et al. Cancer-testis antigens are commonly expressed in multiple myeloma and induce systemic immunity following allogeneic stem cell transplantation. Blood. 2007; 109(3): 1103-12[DOI][PubMed]
  • 31. Evans JP. Fertilin beta and other ADAMs as integrin ligands: insights into cell adhesion and fertilization. Bioessays. 2001; 23(7): 628-39[DOI][PubMed]
  • 32. Turner RM, Musse MP, Mandal A, Klotz K, Jayes FC, Herr JC, et al. Molecular genetic analysis of two human sperm fibrous sheath proteins, AKAP4 and AKAP3, in men with dysplasia of the fibrous sheath. J Androl. 2001; 22(2): 302-15[PubMed]
  • 33. Chiriva-Internati M, Ferrari R, Yu Y, Hamrick C, Gagliano N, Grizzi F, et al. AKAP-4: a novel cancer testis antigen for multiple myeloma. Br J Haematol. 2008; 140(4): 465-8[DOI][PubMed]
  • 34. Andrade VC, Vettore AL, Felix RS, Almeida MS, Carvalho F, Oliveira JS, et al. Prognostic impact of cancer/testis antigen expression in advanced stage multiple myeloma patients. Cancer Immun. 2008; 8: 2[PubMed]
  • 35. van Baren N, Brasseur F, Godelaine D, Hames G, Ferrant A, Lehmann F, et al. Genes encoding tumor-specific antigens are expressed in human myeloma cells. Blood. 1999; 94(4): 1156-64[PubMed]
  • 36. Condomines M, Hose D, Raynaud P, Hundemer M, De Vos J, Baudard M, et al. Cancer/testis genes in multiple myeloma: expression patterns and prognosis value determined by microarray analysis. J Immunol. 2007; 178(5): 3307-15[PubMed]
  • 37. Hayama S, Daigo Y, Kato T, Ishikawa N, Yamabuki T, Miyamoto M, et al. Activation of CDCA1-KNTC2, members of centromere protein complex, involved in pulmonary carcinogenesis. Cancer Res. 2006; 66(21): 10339-48[DOI][PubMed]
  • 38. Sayer JA, Otto EA, O'Toole JF, Nurnberg G, Kennedy MA, Becker C, et al. The centrosomal protein nephrocystin-6 is mutated in Joubert syndrome and activates transcription factor ATF4. Nat Genet. 2006; 38(6): 674-81[DOI][PubMed]
  • 39. Zhao WM, Seki A, Fang G. Cep55, a microtubule-bundling protein, associates with centralspindlin to control the midbody integrity and cell abscission during cytokinesis. Mol Biol Cell. 2006; 17(9): 3881-96[DOI][PubMed]
  • 40. Richardson P, Barlogie B, Berenson J, Singhal S, Jagannath S, Irwin D. Prognostic factors associated with response in patients with relapsed and refractory multiple myeloma (MM) treated with bortezomib. Proc Am Soc Clin Oncol. 2003;
  • 41. Liggins AP, Lim SH, Soilleux EJ, Pulford K, Banham AH. A panel of cancer-testis genes exhibiting broad-spectrum expression in haematological malignancies. Cancer Immun. 2010; 10: 8[PubMed]
  • 42. Moreaux J, Klein B, Bataille R, Descamps G, Maiga S, Hose D, et al. A high-risk signature for patients with multiple myeloma established from the molecular classification of human myeloma cell lines. Haematologica. 2011; 96(4): 574-82[DOI][PubMed]
  • 43. Condomines M, Hose D, Reme T, Requirand G, Hundemer M, Schoenhals M, et al. Gene expression profiling and real-time PCR analyses identify novel potential cancer-testis antigens in multiple myeloma. J Immunol. 2009; 183(2): 832-40[DOI][PubMed]
  • 44. Tinguely M, Jenni B, Knights A, Lopes B, Korol D, Rousson V, et al. MAGE-C1/CT-7 expression in plasma cell myeloma: sub-cellular localization impacts on clinical outcome. Cancer Sci. 2008; 99(4): 720-5[DOI][PubMed]
  • 45. clinicaltrials.gov. . Study of MAGE-A3 and NY-ESO-1 Immunotherapy in Combo With DTPACE Chemo and Auto Transplantation in Multiple Myeloma.
  • 46. Nuber N, Curioni-Fontecedro A, Matter C, Soldini D, Tiercy JM, von Boehmer L, et al. Fine analysis of spontaneous MAGE-C1/CT7-specific immunity in melanoma patients. Proc Natl Acad Sci U S A. 2010; 107(34): 15187-92[DOI][PubMed]
  • 47. Lim SH, Austin S, Owen-Jones E, Robinson L. Expression of testicular genes in haematological malignancies. Br J Cancer. 1999; 81(7): 1162-4[DOI][PubMed]
  • 48. Lethe B, Lucas S, Michaux L, De Smet C, Godelaine D, Serrano A, et al. LAGE-1, a new gene with tumor specificity. Int J Cancer. 1998; 76(6): 903-8[PubMed]
  • 49. Chomez P, De Backer O, Bertrand M, De Plaen E, Boon T, Lucas S. An overview of the MAGE gene family with the identification of all human members of the family. Cancer Res. 2001; 61(14): 5544-51[PubMed]
  • 50. Yang B, O'Herrin S, Wu J, Reagan-Shaw S, Ma Y, Nihal M, et al. Select cancer testes antigens of the MAGE-A, -B, and -C families are expressed in mast cell lines and promote cell viability in vitro and in vivo. J Invest Dermatol. 2007; 127(2): 267-75[DOI][PubMed]
  • 51. van der Bruggen P, Traversari C, Chomez P, Lurquin C, De Plaen E, Van den Eynde B, et al. A gene encoding an antigen recognized by cytolytic T lymphocytes on a human melanoma. Science. 1991; 254(5038): 1643-7[PubMed]
  • 52. Atanackovic D, Hildebrandt Y, Jadczak A, Cao Y, Luetkens T, Meyer S, et al. Cancer-testis antigens MAGE-C1/CT7 and MAGE-A3 promote the survival of multiple myeloma cells. Haematologica. 2010; 95(5): 785-93[DOI][PubMed]
  • 53. Gure AO, Chua R, Williamson B, Gonen M, Ferrera CA, Gnjatic S, et al. Cancer-testis genes are coordinately expressed and are markers of poor outcome in non-small cell lung cancer. Clin Cancer Res. 2005; 11(22): 8055-62[DOI][PubMed]
  • 54. Cho HJ, Caballero OL, Gnjatic S, Andrade VC, Colleoni GW, Vettore AL, et al. Physical interaction of two cancer-testis antigens, MAGE-C1 (CT7) and NY-ESO-1 (CT6). Cancer Immun. 2006; 6: 12[PubMed]
  • 55. Dhodapkar MV, Osman K, Teruya-Feldstein J, Filippa D, Hedvat CV, Iversen K, et al. Expression of cancer/testis (CT) antigens MAGE-A1, MAGE-A3, MAGE-A4, CT-7, and NY-ESO-1 in malignant gammopathies is heterogeneous and correlates with site, stage and risk status of disease. Cancer Immun. 2003; 3: 9[PubMed]
  • 56. Jungbluth AA, Ely S, DiLiberto M, Niesvizky R, Williamson B, Frosina D, et al. The cancer-testis antigens CT7 (MAGE-C1) and MAGE-A3/6 are commonly expressed in multiple myeloma and correlate with plasma-cell proliferation. Blood. 2005; 106(1): 167-74[DOI][PubMed]
  • 57. de Carvalho F, Costa ET, Camargo AA, Gregorio JC, Masotti C, Andrade VC, et al. Targeting MAGE-C1/CT7 expression increases cell sensitivity to the proteasome inhibitor bortezomib in multiple myeloma cell lines. PLoS One. 2011; 6(11)[DOI][PubMed]
  • 58. Pabst C, Zustin J, Jacobsen F, Luetkens T, Kroger N, Schilling G, et al. Expression and prognostic relevance of MAGE-C1/CT7 and MAGE-C2/CT10 in osteolytic lesions of patients with multiple myeloma. Exp Mol Pathol. 2010; 89(2): 175-81[DOI][PubMed]
  • 59. Lendvai N, Gnjatic S, Ritter E, Mangone M, Austin W, Reyner K, et al. Cellular immune responses against CT7 (MAGE-C1) and humoral responses against other cancer-testis antigens in multiple myeloma patients. Cancer Immun. 2010; 10: 4[PubMed]
  • 60. Anderson LJ, Cook DR, Yamamoto TN, Berger C, Maloney DG, Riddell SR. Identification of MAGE-C1 (CT-7) epitopes for T-cell therapy of multiple myeloma. Cancer Immunol Immunother. 2011; 60(7): 985-97[DOI][PubMed]
  • 61. van Rhee F, Szmania SM, Zhan F, Gupta SK, Pomtree M, Lin P, et al. NY-ESO-1 is highly expressed in poor-prognosis multiple myeloma and induces spontaneous humoral and cellular immune responses. Blood. 2005; 105(10): 3939-44[DOI][PubMed]
  • 62. Chiriva-Internati M, Mirandola L, Yu Y, Jenkins MR, Gornati R, Bernardini G, et al. Cancer testis antigen, ropporin, is a potential target for multiple myeloma immunotherapy. J Immunother. 2011; 34(6): 490-9[DOI][PubMed]
  • 63. Yousef S, Heise J, Lajmi N, Bartels K, Kroger N, Luetkens T, et al. Cancer-testis antigen SLLP1 represents a promising target for the immunotherapy of multiple myeloma. J Transl Med. 2015; 13: 197[DOI][PubMed]
  • 64. Wang Z, Zhang Y, Liu H, Salati E, Chiriva-Internati M, Lim SH. Gene expression and immunologic consequence of SPAN-Xb in myeloma and other hematologic malignancies. Blood. 2003; 101(3): 955-60[DOI][PubMed]
  • 65. Frank C, Hundemer M, Ho AD, Goldschmidt H, Witzens-Harig M. Cellular immune responses against the cancer-testis antigen SPAN-XB in healthy donors and patients with multiple myeloma. Leuk Lymphoma. 2008; 49(4): 779-85[DOI][PubMed]
  • 66. Taylor BJ, Reiman T, Pittman JA, Keats JJ, de Bruijn DR, Mant MJ, et al. SSX cancer testis antigens are expressed in most multiple myeloma patients: co-expression of SSX1, 2, 4, and 5 correlates with adverse prognosis and high frequencies of SSX-positive PCs. J Immunother. 2005; 28(6): 564-75[PubMed]
  • 67. He L, Ji JN, Liu SQ, Xue E, Liang Q, Ma Z. Expression of cancer-testis antigen in multiple myeloma. J Huazhong Univ Sci Technolog Med Sci. 2014; 34(2): 181-5[DOI][PubMed]
  • 68. Fontecedro AC, Knights A, Tinguely M, Rosa O, Lopes B, Moch H. Expression and immunogenicity of the cancer-testis antigen CT7 (MAGE-C1) in patients with multiple myeloma. J Clin Oncol (ASCO Annual Meeting). 2007; 25: 8112
  • 69. Goodyear O, Piper K, Khan N, Starczynski J, Mahendra P, Pratt G, et al. CD8+ T cells specific for cancer germline gene antigens are found in many patients with multiple myeloma, and their frequency correlates with disease burden. Blood. 2005; 106(13): 4217-24[DOI][PubMed]
  • 70. Szmania S, Gnjatic S, Tricot G, Stone K, Zhan F, Moreno A, et al. Immunization with a recombinant MAGE-A3 protein after high-dose therapy for myeloma. J Immunother. 2007; 30(8): 847-54[DOI][PubMed]
  • 71. Esfandiary A, Ghafouri-Fard S. MAGE-A3: an immunogenic target used in clinical practice. Immunotherapy. 2015; 7(6): 683-704[DOI][PubMed]
  • 72. Esfandiary A, Ghafouri-Fard S. New York esophageal squamous cell carcinoma-1 and cancer immunotherapy. Immunotherapy. 2015; 7(4): 411-39[DOI][PubMed]
  • 73. Sahota SS, Goonewardena CM, Cooper CD, Liggins AP, Ait-Tahar K, Zojer N, et al. PASD1 is a potential multiple myeloma-associated antigen. Blood. 2006; 108(12): 3953-5[DOI][PubMed]
  • 74. Vaccination with MAGE-3 Protein Can Induce a Potent Immune Response in a Healthy Donor Which Can Be Adoptively Transferred Via Stem Cell Transplant (Tx) to a Multiple Myeloma (MM) Patient. ASH Annual Meeting Abstracts. : 2197
  • 75. Rapoport AP, Aqui NA, Stadtmauer EA, Vogl DT, Xu YY, Kalos M, et al. Combination immunotherapy after ASCT for multiple myeloma using MAGE-A3/Poly-ICLC immunizations followed by adoptive transfer of vaccine-primed and costimulated autologous T cells. Clin Cancer Res. 2014; 20(5): 1355-65[DOI][PubMed]
  • 76. clinicaltrials.gov. . Combination Immunotherapy and Autologous Stem Cell Transplantation for Myeloma.
  • 77. clinicaltrials.gov. . MAGE-A3 Protein + AS15 as Consolidation for Multiple Myeloma Patients Undergoing Autologous Stem Cell Transplantation.
  • 78. clinicaltrials.gov. . Redirected Auto T Cells for Advanced Myeloma.
  • 79. clinicaltrials.gov. . CT7, MAGE-A3, and WT1 mRNA-electroporated Autologous Langerhans-type Dendritic Cells as Consolidation for Multiple Myeloma Patients Undergoing Autologous Stem Cell Transplantation.
  • 80. clinicaltrials.gov. . CT Antigen TCR-Engineered T Cells for Myeloma.
  • 81. clinicaltrials.gov. . Tumor-Associated Antigen-Specific Cytotoxic T-Lymphocytes for Multiple Myeloma (TACTAM) .
  • 82. Stauss HJ, Morris EC. Immunotherapy with gene-modified T cells: limiting side effects provides new challenges. Gene Ther. 2013; 20(11): 1029-32[DOI][PubMed]
  • 83. Cruz CR, Hanley PJ, Liu H, Torrano V, Lin YF, Arce JA, et al. Adverse events following infusion of T cells for adoptive immunotherapy: a 10-year experience. Cytotherapy. 2010; 12(6): 743-9[DOI][PubMed]
  • 84. Anguille S, Smits EL, Lion E, van Tendeloo VF, Berneman ZN. Clinical use of dendritic cells for cancer therapy. Lancet Oncol. 2014; 15(7)-67[DOI][PubMed]
  • 85. Hansel TT, Kropshofer H, Singer T, Mitchell JA, George AJ. The safety and side effects of monoclonal antibodies. Nat Rev Drug Discov. 2010; 9(4): 325-38[DOI][PubMed]
  • 86. Meklat F, Li Z, Wang Z, Zhang Y, Zhang J, Jewell A, et al. Cancer-testis antigens in haematological malignancies. Br J Haematol. 2007; 136(6): 769-76[DOI][PubMed]
Creative Commons License Except where otherwise noted, this work is licensed under Creative Commons Attribution Non Commercial 4.0 International License .

Search Relations:

Author(s):

Article(s):

Create Citiation Alert
via Google Reader

Readers' Comments